Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with Chemotherapy for Resectable Gastroesophageal Adenocarcinoma
NCT01182610Phase 2
Key facts
- Status
- Terminated
- Start
- Apr 2011
- Primary completion
- Mar 2012
- Countries
- 1
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Drugs
- panitumumab
- Conditions
- gastroesophageal adenocarcinoma
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in gastroesophageal adenocarcinoma, sponsored by Accelerated Community Oncology Research Network. Primary endpoint: Response Rate. Started Apr 2011; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Treatment group
Panitumumab + Paclitaxel + Carboplatin + 5FU followed by surgery
03
Who it enrols
Patients with biopsy-proven, potentially resectable adenocarcinoma of the distal esophagus, GE junction, or proximal stomach, ECOG 0-1, and no prior treatment.
04
Endpoints
Primary
Response Rate
Secondary
Pathologic Response Rate
Resection Rate of Surgery
Thirty-day Surgical Mortality
Survival
Beyond the preview
Go deeper on NCT01182610.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01182610.